Phase 3 trial of vorolanib intravitreal insert, using a tyrosine kinase inhibitor (TKI), will be evaluating for wet age-related macular degeneration (wet AMD).
A Phase 3 randomised clinical trial has recruited of >400 patients in a seven-month period, driven by clinical and patient interest, according to the trial’s… Read More »Phase 3 trial of vorolanib intravitreal insert, using a tyrosine kinase inhibitor (TKI), will be evaluating for wet age-related macular degeneration (wet AMD).